A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years
NCT05313893 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 252
Last updated 2022-08-17
Summary
Routine annual influenza vaccination is recommended for all persons aged≥6 months who do not have contraindications. For those aged 6 monthsthrough 8 years who have previously received ≥2 total doses of trivalent orquadrivalent influenza vaccine ≥4 weeks apart, they require only 1 dose ofinfluenza vaccine. For those who have not previously received ≥2 doses oftrivalent or quadrivalent influenza vaccine, they require 2 dose of influenzavaccine. but the evidence on how to select vaccine doses for quadrivalentinfluenza vaccine is limited in China. The study is a prospective, open-labelcomparison of the immunogenicity and reactogenicity of 1 versus 2 doses ofan inactivated quadrivalent influenza vaccine in subjects of 3-8 years old withdifferent history of influenza vaccination.
Conditions
Interventions
- BIOLOGICAL
-
Quadrivalent influenza vaccine
Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
Sponsors & Collaborators
-
Jiangsu Province Centers for Disease Control and Prevention
lead NETWORK
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 3 Years
- Max Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-09-11
- Primary Completion
- 2021-12-25
- Completion
- 2022-05-30
Countries
- China
Study Locations
More Related Trials
-
A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months
NCT05645900 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
NCT03859141 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)
NCT03853993 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
NCT06049927 ·Status: COMPLETED ·Phase: PHASE3
-
Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years
NCT06095947 ·Status: COMPLETED
-
A Clinical Trial of A Quadrivalent Influenza Vaccine
NCT03744104 ·Status: COMPLETED ·Phase: PHASE3
-
The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) (Children Forms of Drug)
NCT01551823 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
NCT05245552 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older
NCT02710409 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older
NCT07332689 ·Status: COMPLETED
-
Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
NCT04363359 ·Status: COMPLETED ·Phase: PHASE2
-
Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine
NCT05642078 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
NCT01992107 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older
NCT02708173 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.
NCT06334510 ·Status: COMPLETED
-
Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60
NCT02806804 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine
NCT03391193 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months
NCT03020628 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children
NCT00900991 ·Status: COMPLETED ·Phase: PHASE2
-
Phase IV Clinical Trial of an Influenza Split Vaccine Anflu
NCT00556062 ·Status: COMPLETED ·Phase: PHASE4
-
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
NCT06800950 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Clinical Trial With Influenza A/H1N1 Vaccines
NCT00956111 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Influenza Virus Vaccines in Children and Adults
NCT00988143 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month
NCT01040078 ·Status: UNKNOWN ·Phase: PHASE3
-
Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine
NCT05471531 ·Status: COMPLETED ·Phase: PHASE4